Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

The firm continues to see molecule compression in the US for Humira, with "volume moving to other novel mechanisms, which has resulted in a benefit to both Skyrizi and Rinvoq," Stewart said.

AbbVie ABBV stock has gained 16.1% so far this year compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.

AbbVie’s immunology blockbusters Rinvoq and Skyrizi took the first and second slots, respectively, for the month, resuming the custom they upheld throughout most of 2024. Those gains over ...

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

AbbVie has successfully navigated the loss of exclusivity (LOE) of its blockbuster drug, Humira, by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are ...

In patients with prior tumour necrosis factor exposure, therapies with alternative mechanisms such as Janus ... with Rinvoq and Skyrizi gaining traction just as Humira’s role diminishes.